Dauntless Investment Group LLC Purchases Shares of 70,848 enVVeno Medical Corporation (NASDAQ:NVNO)

Key Points

• Dauntless Investment Group LLC has acquired 70,848 shares of enVVeno Medical Corporation, worth approximately $186,000, representing about 0.40% of the company's stock.
• Other institutional investors, including Jane Street Group and Virtu Financial, also purchased new positions in enVVeno Medical during the 4th quarter, contributing to a total institutional ownership of 34.71%.
• enVVeno Medical's stock opened at $5.17 and has shown a one-year trading range between a low of $2.03 and a high of $5.91, with reported earnings of ($0.22) EPS for the quarter.

Dauntless Investment Group LLC purchased a new stake in shares of enVVeno Medical Corporation (NASDAQ:NVNO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 70,848 shares of the company's stock, valued at approximately $186,000. Dauntless Investment Group LLC owned approximately 0.40% of enVVeno Medical at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in enVVeno Medical during the 4th quarter valued at approximately $56,000. National Bank of Canada FI purchased a new position in enVVeno Medical during the 4th quarter valued at approximately $60,000. Virtu Financial LLC purchased a new position in enVVeno Medical during the 4th quarter valued at approximately $86,000. Marshall Wace LLP purchased a new position in enVVeno Medical during the 4th quarter valued at approximately $147,000. Finally, Northern Trust Corp grew its holdings in enVVeno Medical by 68.3% during the 4th quarter. Northern Trust Corp now owns 56,725 shares of the company's stock valued at $171,000 after buying an additional 23,029 shares in the last quarter. Hedge funds and other institutional investors own 34.71% of the company's stock.

enVVeno Medical Stock Performance

Shares of enVVeno Medical stock opened at $5.17 on Tuesday. The stock has a market cap of $90.68 million, a price-to-earnings ratio of -4.38 and a beta of 0.93. The stock has a 50 day moving average price of $4.15 and a 200-day moving average price of $3.44. enVVeno Medical Corporation has a one year low of $2.03 and a one year high of $5.91.

enVVeno Medical (NASDAQ:NVNO - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.22) EPS for the quarter. Sell-side analysts predict that enVVeno Medical Corporation will post -1.32 earnings per share for the current fiscal year.

enVVeno Medical Company Profile

enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Want to see what other hedge funds are holding NVNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enVVeno Medical Corporation (NASDAQ:NVNO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.